Two immunogenicity and reactogenicity studies (Com-COV & CombiVacS) on heterologous prime-boost published.

AZ+Pfizer data is very reassuring, good binding + neutralizing antibodies and T-cell responses. Side effect profile typical, mild to moderate and transient.